Decision Resources’ European Physician & Payer Forum report “Tightening Healthcare Budgets and Elevated Cost-Effectiveness Expectations: How Will Payers and Prescribers Prioritize Targeted Agents for Breast Cancer in the EU5?” draws on insights from 259 surveyed medical oncologists in the EU5 and from interviews with 15 European payers, all of whom have influence at a national or regional level. Interviewed payers include the following:
France: A national payer and past member of the Transparency Commission (CT), hospital head pharmacists.
Germany: An affiliate of the Joint Federal Committee of Physicians, Dentists, Hospitals, and Health Insurance Funds (GBA); a senior oncology consultant who is chair of the hospital formulary committee; a pharmacy director and member of the Federal Pharmacy Association.
Italy: Italian Medicines Agency (AIFA) advisors and a hospital head pharmacist from various Italian regions.
Spain: Pharmacy directors and regional formulary committee members from various autonomous communities.
United Kingdom: A Clinical Commissioning Group (CCG) and acute trust pharmaceutical advisor; a chief pharmacist and hospital formulary committee chair; a CCG head of medicines management.